Brought to you by 
Codexis researches fermentation methods for Lilly: terminated
23 Jul 2008
Executive Summary
Codexis signed a multi-year agreement to develop improved fermentation methods for producing several of Eli Lilly's natural product drugs. Codexis uses DNA shuffling technologies from its parent, Maxygen, to engineer biocatalysts and design processes for chemical production.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Synthesis Technologies, Production Processes
-
Drug Discovery Tools
- Genomics-Proteomics
Deal Status
- Terminated
Deal Type
-
Alliance
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Codexis researches fermentation methods for Lilly: terminated
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice